Methods For Treating Bleeding
AssigneeMaxygen Holdings Ltd.
InventorsMads Ropke, Stephanie J. Lathrop
Life of this patent
Estimating the term…
Abstract
Methods for the treatment of various bleeding disorders using variants of human Factor VII (hFVII) or activated FVII (FVIIa) having an altered activity compared to 5 recombinant FVIIa with the native human sequence.
Claims26
A method for treatment of bleeding in a patient, wherein the bleeding is associated with trauma, intracerebral hemorrhage (ICH), traumatic brain injury (TBI), burns, variceal bleeds, gastrointestinal bleeding, surgical bleeds, transplantation, fibrinolytic treatment, anticoagulant treatment, postpartum hemorrhage, viral-induced hemorrhage, thrombocytopenia, or factor deficiency, comprising administering to said patient a variant of a human FVII or FVIIa polypeptide that differs from SEQ ID NO:1 in 1-15 amino acid residues and has an increased phospholipid membrane binding affinity and/or an increased tissue factor independent activity relative to hFVIIa.
(canceled)
Dependencies are inferred from the claim text.